FDA Approves New Antibody to Slow Alzheimer’s Disease, Even as Safety Concerns Linger

The US FDA approved a controversial Alzheimer’s disease treatment for broad use—with caveats. The drug, an antibody called lecanemab, is the first to clearly slow cognitive decline in patients with early-stage disease, fueling excitement in the Alzheimer’s field and hope for patients and families.